Chimeric Antigen Receptor (CAR) Modified T-Cells for ALL

This information was originally presented on September 19, 2014, at the NCCN 9th Annual Congress: Hematologic Malignancies™ held in New York, New York.

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

  • Analyze the role of CAR T-cells as an adoptive therapy for relapsed/refractory ALL
Additional information
Supporters: 

Supported by educational grants from Foundation Medicine, Inc.; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Pharmacyclics, Inc. and Janssen Biotech, Inc.; and Takeda Oncology

Course summary
Available credit: 
  • 0.50 Participation
  • 0.49 Nurse
  • 0.50 Pharmacist
  • 0.50 Physician
Course opens: 
11/06/2014
Course expires: 
11/06/2015
Cost:
$0.00

Jae H. Park, MD
Memorial Sloan Kettering Cancer Center

Available Credit

  • 0.50 Participation
  • 0.49 Nurse
  • 0.50 Pharmacist
  • 0.50 Physician

Accreditation Period

Course opens: 
11/06/2014
Course expires: 
11/06/2015

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • Adobe Reader for certificate viewing/printing